1. Merck to buy Pandion for $1.9B for its immune modulators — Biden looking beyond Woodcock or Sharfstein for FDA commmisioner — Former AveXis execs launch gene therapy startup See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice

Nuvasive stock holders jab Directors

Discussion in 'NuVasive' started by Anonymous, Jun 8, 2012 at 10:20 AM.

  1. Anonymous

    Anonymous Guest

    Nuvasive's latest SEC filing says the Stock Holders voted against compensating the Directors:


    """"""Approval by the Company's stockholders by advisory (non-binding) vote on the
    compensation of the Company's named executive officers, as disclosed in the
    Company's proxy statement for the Annual Meeting pursuant to the compensation
    disclosure rules of the SEC, failed by the following vote:

    Votes Votes Broker
    For Against Abstentions Non-Votes
    11,520,323 23,651,374 149,382 3,769,575"""""""""

  2. Anonymous

    Anonymous Guest

    Also read the statement at the bottom of that link in Nuvasive's SEC filing.

    Sounds like Company performance ain't doing so well. Bosses are getting compensation cut severely.
  3. Anonymous

    Anonymous Guest

    Looks like the Director they just put in charge is an Australian.
  4. Anonymous

    Anonymous Guest


    Profitability / Profit Margin = -12.60%

    Return on Equity = -14.84%

    Quarterly Earnings Growth (year over year) = -71.50%

    Net Income Available to Common Stockholders = -$71.54 Million

    What's that last one about? Sounds dire.